|
...compared to $1.3 million, or $0.05 per share, for the same period in 2005. The commercial launch activities for Zenvia (formerly referred to as Neurodex) increased AVANIR's operating expenses in the period, which contributed to significant part of the increase in net loss compared with the same period a year ago.
Subsequent to the close of the fourth quarter of fiscal 2006, AVANIR: Received an approvable letter from the U.S. Food and Drug Administration for Zenvia for the treatment of involuntary emotional expression disorder (IEED). They have scheduled a meeting with the FDA in the first quarter of calendar 2007 and will provide an update on the path forward once that is determined.
Completed an equity offering raising approximately $14.4 million of net proceeds. As required by the note obligation associated with our acquisition...
NOTE: All illustrations and photos
have been removed from this article.
More articles from Biotech Financial Reports
ICON 2007 EPS FORECAST TO GROW 29% COMPARED TO 2006.(Brief article), January 01, 2007
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
(financial%20report)%20%20&position=1)